Rapastinel

雷帕替奈

Report date: 2025/06/09 14:19:28
NME

Base Information

Drug NameRapastinel
Drug Alias NameRapastinelumGLYX-13-peptideGLYX-13-trifluoroacetateTPPT-amideTPPT-amide-trifluoroacetate +[9] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlutamate [NMDA] receptor agonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsDepressive Disorder, MajorObsessive-Compulsive DisorderMental Disorders +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSlovakia +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNorthwestern University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNaurex, Inc, An Affiliate Of Allergan PlcNew York State Psychiatric InstituteGate Neurosciences Inc +[4] 
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorObsessive-Compulsive DisorderMental Disorders +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia